Search - tctmd.com

Displaying 21 - 40 of 334

Sort: Relevancy | Date

News Conference News

‘Healing’ Stent Noninferior to Permanent-Polymer Device: PIONEER III

Shelley Wood

November 19, 2020

The OPTIMIZE IDE: TrialProspective, Randomized Evaluation of Sirolimus-Eluting Coronary Stents with Fixed-Wire and Rapid-Exchange Delivery Systems and a Novel Bioresorbable Drug Carrier

Presentation TCT 2020

OPTIMIZE IDE: Trial Prospective, Randomized Evaluation of Sirolimus-Eluting Coronary Stents with Fixed-Wire and Rapid-Exchange Delivery Systems and a Novel Bioresorbable Drug Carrier

Presenter: Dean J. Kereiakes

October 17, 2020

News Conference News TCT 2020

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

Shelley Wood

October 17, 2020

News Conference News ACC 2020

TICO: Ticagrelor Monotherapy After 3 Months of DAPT Curbs Bleeding in Stented ACS Patients

Todd Neale

March 31, 2020

News Conference News CRT 2020

Newer, Thinner-Strut Abbott Scaffold Prompts Talk of a BVS Comeback

Michael O'Riordan

February 28, 2020

News Conference News CRT 2020

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

L.A. McKeown

February 25, 2020

News Daily News

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

Michael O'Riordan

February 10, 2020

News Conference News LINC 2020

COMPARE: Similar Efficacy and Safety for Paclitaxel Balloons Regardless of Dose

L.A. McKeown

January 28, 2020

News Conference News VIVA 2019

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

L.A. McKeown

November 06, 2019

News Conference News TCT 2019

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

Michael O'Riordan

September 30, 2019

News Conference News TCT 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

Caitlin E. Cox

September 26, 2019

Presentation TCT 2019

TCT 47: Five-Year Clinical Outcomes From Randomized Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents in Patients With Coronary Artery Disease From ABSORB China Trial

Presenter: Run-Lin Gao

September 25, 2019

Presentation TCT 2019

TCT 11: Everolimus-eluting Bioresorbable Scaffolds versus Drug-eluting Stents in Patients with Acute Myocardial Infarction – 2-Year Results of the Randomized ISAR-Absorb MI Trial

Presenter: Jens Wiebe

September 25, 2019

Presentation TCT 2019

TCT 42: Polymer-free Drug-coated vs. Bare-metal Coronary Stents in Patients Undergoing Non-cardiac Surgery A Subgroup Analysis of the LEADERS FREE Trial

Presenter: Abdelhakim Allali

September 25, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for August 2019

Shelley Wood

August 30, 2019

News Daily News

More Acute Stent Thrombosis With Synergy Stent in Bern PCI Registry

Michael O'Riordan

August 14, 2019

Podcast TCTMD Talking Points

COMPARE ABSORB: A Randomized Trial of a Polymeric Everolimus-Eluting Bioresorbable Scaffold in High-Risk and Complex Lesions

July 17, 2019

News Conference News EuroPCR 2019

Daring to Dream: New BRS Data Hint at Low MACE Rates at 2 and 3 Years

Michael O'Riordan

May 27, 2019

News Conference News EuroPCR 2019

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

Shelley Wood

May 16, 2019

News Daily News

Three Years On, Absorb BVS Still Doesn’t Improve Myocardial Blood Flow

Michael O'Riordan

April 30, 2019

Advertisement

‘Healing’ Stent Noninferior to Permanent-Polymer Device: PIONEER III

OPTIMIZE IDE: Trial Prospective, Randomized Evaluation of Sirolimus-Eluting Coronary Stents with Fixed-Wire and Rapid-Exchange Delivery Systems and a Novel Bioresorbable Drug Carrier

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

TICO: Ticagrelor Monotherapy After 3 Months of DAPT Curbs Bleeding in Stented ACS Patients

Newer, Thinner-Strut Abbott Scaffold Prompts Talk of a BVS Comeback

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

COMPARE: Similar Efficacy and Safety for Paclitaxel Balloons Regardless of Dose

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

TCT 47: Five-Year Clinical Outcomes From Randomized Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents in Patients With Coronary Artery Disease From ABSORB China Trial

TCT 11: Everolimus-eluting Bioresorbable Scaffolds versus Drug-eluting Stents in Patients with Acute Myocardial Infarction – 2-Year Results of the Randomized ISAR-Absorb MI Trial

TCT 42: Polymer-free Drug-coated vs. Bare-metal Coronary Stents in Patients Undergoing Non-cardiac Surgery A Subgroup Analysis of the LEADERS FREE Trial

TCTMD’s Top 10 Most Popular Stories for August 2019

More Acute Stent Thrombosis With Synergy Stent in Bern PCI Registry

COMPARE ABSORB: A Randomized Trial of a Polymeric Everolimus-Eluting Bioresorbable Scaffold in High-Risk and Complex Lesions

Daring to Dream: New BRS Data Hint at Low MACE Rates at 2 and 3 Years

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

Three Years On, Absorb BVS Still Doesn’t Improve Myocardial Blood Flow

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content